Abstract:Abstract Background In the population of postmenopausal patients with major depressive disorder (MDD), the superiority of serotonin-norepinephrine reuptake inhibitors (SNRIs) over selective serotonin reuptake inhibitors (SSRIs) has not yet been definitively proven. Consequently, a direct comparison of the efficacy of SSRIs and SNRIs in the treatment of postmenopausal depression could provide relevant data. The aim of this study was to compare the efficacy and safety of venlafaxine vs. fluoxetine in the treatment of postmenopausal MDD. Methods This was an 8-week, multicenter, randomized, single-blind, active-controlled trial conducted at a psychiatric hospital (Beijing Anding Hospital) and a general hospital (Beijing Chaoyang Hospital) between April 2013 and September 2017. The primary outcome measure was improving depressive symptoms (Hamilton Depression Rating Scale (HAMD-24) score). The secondary outcomes included the change of HAMD-24 anxiety/somatization factor score and Clinical Global Impressions-Improvement (CGI-I) response rate. Safety was assessed by treatment-emergent adverse events (TEAEs) and laboratory tests. Efficacy was analyzed by using the full analysis set (FAS) following the modified intention-to-treat (mITT) principle. The primary endpoint measurements were analyzed using a mixed-effect model for repeated measures (MMRM) model with patients as a random-effect factor, treatment group as the independent variable, time as a repeated measure, and baseline covariates, using a first-order ante dependence covariance matrix. Results A total of 184 women were randomized. The full analysis set (FAS) included 172 patients (venlafaxine, n = 82; fluoxetine, n = 90). Over the 8-week study period, the reduction in HAMD-24 scores was significant ( P < 0.001) in both groups, while a significantly greater decline from baseline was observed in the venlafaxine group compared with the fluoxetine group (least-squares mean difference [95% CI]: − 2.22 [− 7.08, − 0.41]), P = 0.001). The baseline-to-week-8 least-squares mean change of the anxiety/somatization factor scores, CGI-I response rate were greater in the venlafaxine group than in the fluoxetine group (all P < 0.05). The most frequent TEAEs (≥5%) in both groups were nausea, somnolence, dizziness, headache, and dry mouth. There was no significant difference in the incidence of adverse events between the two groups. Conclusion Venlafaxine was well tolerated and compared to fluoxetine, it led to a greater improvement in the treatment of postmenopausal MDD. Trial registration Clinical Trials. gov #NCT01824433 . The trial was registered on April 4, 2013.

A Clinical Study of Venlafaxine in the Treatment of Anxiety in Elderly Hypertensive Patients with Anxiety

Venlafaxine vs clomipramine in treating major depression associated with anxiety

Treatment of Depressive Outpatient with Venlafaxine:An Open Clinical Trial

The efficacy and safety of venlafaxine XR in treating patients with major depression in a multicenter,open-label, 16 week study

Randomized,multicenter,double blind comparative trial of reboxetine in the treatment of depression with or without anxiety

A comparison study of sertraline,venlafxin and alprazolam in treatment of generalized anxiety disorder

A comparative study of treatment of depression:Mirtazapine vs.fluoxepine

Expert consensus for clinical appliance of venlafaxine controlled release formulation

Efficacy and safety of olanzapine combined with fluoxetine in treatment of depression

Clinical effects of venlafaxine in treatment of depressive disorder associated with anxiety and its impact factors

Venlafaxine in treating 62 patients with depression: a multicenter open trial

Research on the Effect of Escitalopram and Venlafaxine in the Treatment of Patients with Initial Diagnosis of Major Depressive Disorder

Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study

A parallel control study of venlafaxine and fluoxertine in first-episode patients with depression

Effect of Venlafaxine on Blood Pressure and QTc

Clinical effects of escitalopram in the treatment of senile depression

Pharmacokinetic Bioequivalence and Safety Assessment of Two Venlafaxine Hydrochloride Extended-Release Capsules in Healthy Chinese Subjects Under Fed Conditions: A Randomized, Open-Label, Single-Dose, Crossover Study

Assessing the efficacy and safety of combined buspirone and venlafaxine treatment in late-life depression accompanied by cognitive impairment: A randomized controlled trial

Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study

Escitalopram and sertraline in treatment of depression with anxiety

Efficacy and safety of venlafaxine extended release versus paroxetine for depression:a meta-analysis